Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer

NCT01091428 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

191

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Carcinoma
Fallopian Tube Cancer
Peritoneal Cancer
Breast Carcinoma

Interventions

DRUG: Alisertib
DRUG: Paclitaxel

Sponsor

Millennium Pharmaceuticals, Inc.